Skip to main content

Table 4 Number of people recommended for treatment by QRISK3 and CRISK-CCI, observed event rate, and estimated number needed to treat to prevent an incident CVD event

From: Predictive performance of a competing risk cardiovascular prediction tool CRISK compared to QRISK3 in older people and those with comorbidity: population cohort study

Risk threshold Number recommended for treatment
(% of all people)
Number of CVD
events
(% of all events)
NNT to prevent 1 CVD event*
Women
20%    
  QRISK3 39219 (7.9%) 6084 (47.0%) 25.8
  CRISK-CCI 31,811 (6.4%) 5344 (41.2%) 23.9
10%    
  QRISK3 79,825 (16.1%) 8849 (68.3%) 36.1
  CRISK-CCI 73,029 (14.8%) 8542 (65.9%) 34.2
7.5%    
  QRISK3 100,396 (20.3%) 9718 (75.0%) 41.3
  CRISK-CCI 93,855 (19.0%) 9498 (73.3%) 39.5
Men
20%    
  QRISK3 48,769 (10.3%) 7350 (45.1%) 26.5
  CRISK-CCI 41,517 (8.8%) 6125 (37.6%) 27.1
10%    
  QRISK3 112,632 (23.8%) 11,620 (71.3%) 38.8
  CRISK-CCI 107,371 (22.7%) 11,272 (69.1%) 38.1
7.5%    
  QRISK3 143,424 (30.3%) 12,967 (79.5%) 44.2
  CRISK-CCI 138,352 (29.2%) 12,703 (77.9%) 43.6
  1. *Assuming a 25% risk reduction with primary prevention statin treatment taken by all people recommended for treatment. NNT number needed to treat with statins. CVD cardiovascular disease